MedTrace Logo

An Open-Label Crenezumab Study in Participants With Alzheimer's Disease

NCT03491150 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 149

Last updated 2020-07-13

Study results available
· View outcomes & findings →

Summary

In the BN40031 OLE study, a dose of crenezumab of 60 mg/kg intravenous (IV) every 4 weeks (Q4W) will be offered to all participants who complete Study BN29552 or BN29553 and who meet eligibility criteria in order to evaluate safety in participants on long-term crenezumab treatment and to investigate the effect of crenezumab on the underlying disease process and disease course as an exploratory efficacy objective.

Conditions

Interventions

DRUG

Crenezumab

Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-11
Primary Completion
2019-05-31
Completion
2019-05-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Finland
  • France
  • Germany
  • Hong Kong
  • Italy
  • Lithuania
  • Mexico
  • Poland
  • Russia
  • South Korea
  • Spain
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03491150 on ClinicalTrials.gov